Pharmafocus and Pharmafile

Pharmafocus and Pharmafile
Share

Pharmafocus and Pharmafile

 •  January 17

Celgene has already started off the year with a bang, , and it is reported that it is already in the process of making its second big acquisition of the year. Celgene’s target is Juno Therapeutics – a developer of CAR-T treatments that once held the pole position in the field before deaths in trials finally led the company to abandon its lead...

Pharmafocus and Pharmafile

 •  January 16

US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on behalf of Grünenthal, it has emerged. Mundipharma has signed a licensing and distribution deal with the German pharmaceutical firm which covers a number of forms of the medicine, including Tramal sustained release...

Sri Lanka is set to build its first-ever exclusive pharmaceutical manufacturing zone, it has emerged. The State Pharmaceuticals Manufacturing Corporation of Sri Lanka (SPMC) and Pharma Zone this week entered into an agreement to pursue the investment into the nation’s Kalutara district which comes to a total in excess of US$10 million. Pharma Zone...

Shire has revealed that it now plans to move forward by separating its operations into two distinct divisions: rare disease and neuroscience – a move which follows the first stage of the company’s strategic review which began in August last year. The decision is in part due to the admission by Shire that it had downgraded its total revenue...

It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new offer comes in at €28 per share and is 14% higher than the one the company made on 22 December – a bid which Ablynx rejected. The deal also included an additional €2.50 per share dependent on specific research portfolio conditions. However,...

Takeda already had a strong working relationship with TiGenix, after previously signing a licensing agreement with the Belgium-based pharma company on a treatment for Crohn’s disease. It has now moved to cement the relationship, with a takeover of its smaller partner. The deal works out at an all-cash offer of $630 million, a proposal that has...

Pharmafocus and Pharmafile

 •  December 20, 2017

The deal includes multiple targets and seems to have a similar structure to DiCE’s previous agreement with Sanofi. The exact financials of the deal were not disclosed but it will see DiCE receive an upfront payment, as well as the usual milestones tied into development, regulatory and commercial successes. In DiCE’s deal with Sanofi, this included...

Pharmafocus and Pharmafile

 •  December 15, 2017

When Kare Shultz decided to take on the CEO position at Teva he would have known that he was setting himself up for a challenging time. In the opening period of his tenure, it seems he has taken the strategy to implement changes hard and fast – culminating in the decision to cut the global workforce of the company by over 25%. Many of those cuts...

Pharmafocus and Pharmafile

 •  November 27, 2017

Recipharm, a leading contract development and manufacturing organisation (CDMO) has equipped three more of its facilities with serialisation capabilities in line with the US regulatory requirements in time for today’s introduction of the Drug Supply Chain Security Act (DSCSA). The facilities in Brescia, Italy and Karlskoga and Uppsala, Sweden, are...

Pharmafocus and Pharmafile

 •  November 27, 2017

President Donald Trump’s budget proposes to cut funding to the National Institutes of Health by $7.2 billion or 21%. Researchers at the Washington University School of Medicine assert that this is a move which, given that the NIH funded more than 90% of new drugs, could prove to have dramatic consequences. The team analysed past budget data from...